research use only

Iadademstat (ORY-1001) Dihydrochloride LSD1 Inhibitor

Name: Iadademstat (ORY-1001) Dihydrochloride
Brand: Selleck Chemicals
SKU: S7795
Availability: InStock
Rating: 5 (25 reviews)

Cat.No.S7795

ORY-1001 (RG-6016) 2HCl is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of <20 nM, with high selectivity against related FAD dependent aminoxidases. Phase 1.

Chemical Structure

Molecular Weight: 303.27

Jump to

Quality Control

Batch: Purity: 99.95%

99.95

Related Targets	HDAC JAK BET Histone Methyltransferase PKC PARP HIF PRMT EZH2 AMPK
Other Histone Demethylase Inhibitors	GSK-J4 Hydrochloride SP2509 GSK-LSD1 2HCl JIB-04 CPI-455 HCl OG-L002 IOX1 GSK J1 ML324 CP2

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
THP1	Function assay		13 days	Induction of differentiation of human THP1 cells assessed assessed as alteration in morphology of colonies after 13 days by May Grunwald-Giemsa staining based assay	26702542
THP1	Function assay		13 days	Induction of differentiation of human THP1 cells after 13 days by cytospin assay	26702542
HCT116	Cytotoxicity assay	2 uM	16 to 30 hrs	Cytotoxicity against human HCT116 cells at 2 uM after 16 to 30 hrs by microscopic analysis	29439916
PA1	Cytotoxicity assay	2 uM	16 to 30 hrs	Cytotoxicity against human PA1 cells at 2 uM after 16 to 30 hrs by microscopic analysis	29439916
F9	Cytotoxicity assay	2 uM	16 to 30 hrs	Cytotoxicity against mouse F9 cells at 2 uM after 16 to 30 hrs by microscopic analysis	29439916
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

Water : 61 mg/mL

DMSO : 5 mg/mL (16.48 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 4 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	303.27	Formula	C₁₅H₂₂N₂. 2HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1431326-61-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	RG-6016			SMILES	C1CC(CCC1N)NC2CC2C3=CC=CC=C3.Cl.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	LSD1 20 nM
In vitro	In THP-1 (MLL-AF9) cells, ORY-1001 results in a time/dose dependent me2H3K4 accumulation at KDM1A target genes and concomitant induction of differentiation markers. ORY-1001 also induces apoptosis in THP-1 and inhibits proliferation and colony formation of MV(4;11) (MLL-AF4) cells.
In vivo	In rodent MV(4;11) xenografts, ORY-1001 (<0.020mg/kg, p.o.) leads to significantly reduced tumor growth.
References	[1] http://meetinglibrary.asco.org/content/116240-132 [2] https://pubmed.ncbi.nlm.nih.gov/34958158/

Applications

Methods	Biomarkers	Images	PMID
Growth inhibition assay	Cell number		30568590

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07113691	RECRUITING	Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Yale University	2026-01-20	PHASE1
NCT06287775	RECRUITING	Extensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8	National Cancer Institute (NCI)	2025-04-08	PHASE1; PHASE2
NCT06661915	RECRUITING	Accelerated Phase Myeloproliferative Neoplasm; Blast Phase Myeloproliferative Neoplasm; Essential Thrombocythemia; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Not Otherwise Specified; Polycythemia Vera; Primary Myelofibrosis; Secondary Myelofibrosis	National Cancer Institute (NCI)	2025-08-14	PHASE2
NCT06514261	SUSPENDED	Acute Myeloid Leukemia	National Cancer Institute (NCI)	2024-12-18	PHASE1
NCT06357182	RECRUITING	Acute Myeloid Leukemia; Myelodysplastic Syndrome/Acute Myeloid Leukemia	OHSU Knight Cancer Institute	2024-08-22	PHASE1
NCT06502145	RECRUITING	Myelodysplastic Syndromes	Medical College of Wisconsin	2025-01-10	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):